Pharmacological treatment of hypertension is effective in preventing cardiovascular and renal complications. Calcium antagonists (CAs) and blockers of the renin-angiotensin system [angiotensin-converting enzyme (ACE) inhibitors and angiotensin II antagonists (ARBs)] are widely used today to initiate antihypertensive treatment but, when given as monotherapy, do not suffice in most patients to normalise blood pressure (BP). Combining a CA and either an ACE-inhibitor or an ARB considerably increases the antihypertensive efficacy, but not at the expense of a deterioration of tolerability. Several fixed-dose combinations are available (CA + ACE-inhibitors: amlodipine + benazepril, felodipine + ramipril, verapamil + trandolapril; CA + ARB: amlodipine + valsartan). They are expected not only to improve BP control, but also to facilitate long-term adherence with ON antihypertensive therapy, thereby providing renal damage caused by high BP. maximal protection against the cardiovascular and renal damage caused by high BP.
He J., Whelton PKEpidemiology and prevention of hypertension. Med Clin North Am1997;81:1077-97.
2.
Ezzati M., Lopez AD, Rodgers A., Vander Hoorn S., Murray CJSelected major risk factors and global and regional burden of disease . Lancet2002;360:1347-60.
3.
Kearney PM, Whelton M., Reynolds K., Whelton PK, He J.Worldwide prevalence of hypertension: a systematic review. J Hypertens2004;22:11-19.
4.
Turnbull F. , Neal B., Algert C. et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomised trials . Arch Intern Med2005;165:1410-19.
5.
Staessen JA, Li Y., Thijs L., Wang JGBlood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. Hypertens Res2005;28:385-407.
6.
Dickerson CJE , Hingorani AD, Ashby MJ, Palmer CR, Brown MJOptimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet1999;353:2008-13.
7.
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. JAMA2002;288:2977-81.
8.
Dahlöf B., Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention. For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet2002;359:995-1003.
9.
Pepine CJ, Handberg EM, Cooper-DeHoff RM et al. A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA2003;290:2805-16.
10.
Julius S., Kjeldsen SE, Weber M.et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial . Lancet2004;363:2022-31. 11. Dahlöf B., Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet2005;366:895-906.
11.
Law MR, Wald NJ, Morris JK, Jordan REValue of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ2003 ;326:1427-31.
12.
Dezii CMA retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Managing Care2000;9 (suppl.):2-6.
13.
Chobanian AV , Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension2003;42:1206-52.
14.
Mancia G., De Backer G., Dominiczak A. et al. 2007Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens2007;25:1105-87.
15.
Abernethy DR , Schwartz JBCalcium-antagonist drugs. N Engl J Med1999;341:1447-57.
16.
Luscher TF, Cosentino F.The classification of calcium antagonists and their selection in the treatment of hypertension. Drugs1998;55:509-17.
17.
Grossman E. , Messerli FHCalcium antagonists. Progress Cardiovasc Dis2004;47:34-57.
Grossman E. , Messerli FHLong-term safety of antihypertensive therapy . Progress Cardiovasc Dis2006;49:16-25.
20.
Williams B.Recent hypertension trials: implications and controversies. J Am Coll Cardiol2005;45:813-27.
21.
Sever P.New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society. JRAAS2006;7:61-3.
22.
Mancia G., Dell'Oro R., Quasrti-Trevano F., Scopelliti F., Grassi G.Angiotensin-sympathetic system interactions in cardiovascular and metabolic disease. J Hypertens2006;24 (suppl 1):51-6.
23.
Folkow, B.A Physiological aspects of primary hypertension. Phys Rev1982;62:347-504.
24.
Staessen JA , Wang J., Bianchi G., Birkenhager WHEssential hypertension . Lancet2003;361:1629-41.
25.
Beevers DG, Sleight P.Short acting dihydropyridine (vasodilating) calcium channel blockers for hypertension: is there a risk?BMJ1996 ;312:1143-45.
26.
Grossman E. , Messerli FHEffect of calcium antagonists on plasma norepinephrine levels, heart rate, and blood pressure. Am J Cardiol1997;80:1453-8.
27.
Binggeli C. , Corti R., Sudano I., Luscher TF, Noll G.Noll G.Effects of chronic calcium channel blockade on sympathetic nerve activity in hypertension. Hypertension2002; 39:892-6.
28.
Niarchos AP , Pickering TG, Morganti A., Laragh JHPlasma catecholamines and cardiovascular responses during converting enzyme inhibition in normotensive and hypertensive man. Clin Exper Hypertens1982;4:761-89.
29.
Seljeflot I. , Moan A., Kjeldsen S., Sandvik E., Arnesen H.Effect of angiotensin II receptor blockade on fibrinolysis during acute hyperinsulinemia in patients with essential hypertension . Hypertension1996;27:1299-304.
30.
Miyajima E. , Shigemasa T., Yamada Y., Tochikubo O., Ishii M.Angiotensin II blunts, while an angiotensin-converting enzyme inhibitor augments, reflex sympathetic inhibition in humans. Clin Exp Pharmacol Physiol1999;26:797-802.
31.
Sturani A., Chiarini C., Degliesposti E., Santoro A., Zuccala A., Zucchelli P.Heart rate control in hypertensive patients treated by captopril. Br J Clin Pharmacol1982;14:849-55.
32.
Pancera P., Presciuttini B., Sansone S. et al. Effect of losartan on heart rate and blood pressure variability during tilt test and trinitroglycerine vasodilation. J Hypertens1999;17:513-21.
33.
Kuschnir E. , Acuna E., Sevilla D. et al. Treatment of patients with essential hypertension: amlodipine 5 mg/benazepril 20 mg compared with amlodipine 5 mg, benazepril 20 mg, and placebo. Clin Ther1996;18:1213-24.
34.
Karlberg BE , Andrup MAO.Efficacy and safety of a new long-acting drug combination, trandolapril/verapamil as compared to monotherapy in primary hypertension. Blood Pressure2000 ;9:140-5.
35.
Messerli FH , Oparil S., Feng Z.Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. Am J Cardiol2000;86:1182-7.
36.
Pool J., Kaihlanen P., Lewis G. et al. Once-daily treatment of patients with hypertension: a placebo-controlled study of amlodipine and benazepril vs. amlodipine or benazepril alone. J Hum Hypertens2001;15:495-98.
37.
Messerli FH , Weir MR, Neutel JMCombination therapy of amlodipine/benazepril versus monotherapy of amlodipine in a practice-based setting. Am J Hypertens2002;15:550-6.
38.
Jamerson KA , Nwose O., Jean-Louis L., Schofield L., Purkayastha D., Baron M.Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension . Am J Hypertens2004;17:495-501.
39.
Philipp T., Smith TR, Glazer R. et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther2007;29:563-80.
40.
Neutel JM, Smith DH, Weber MAEffect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass. Am J Hypertens2004;17:37-42.
41.
Hasebe N., Kikuchi K., NICE Combi Study Group.Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study . J Hypertens2005;23:445-53.
42.
Luscher TF, Waeber B.Efficacy and safety of various combination therapies based on a calcium antagonist in essential hypertension: results of a placebo-controlled randomized trial . J Cardiovasc Pharmacol1993;21:305-09.
43.
Letellier P. , Overlack A., Agnes E., Desche P.Perindopril plus nifedipine versus perindopril plus hydrochlorothiazide in mild to severe hypertension: a double-blind multicentre study. J Hum Hypertens1994;8:145-9.
44.
de Leeuw PW , Notter T., Zilles P.Comparison of different fixed antihypertensive combination drug : a double-blind, placebocontrolled parallel group study . J Hypertens1997;15:87-91. 46. Weir MR, Weber MA, Neutel JM, Vendetti J., Michelson EL,
45.
Wang wRY .Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: a clinical experience trial. ACTION Study Investigators.Am J Hypertens2001;14:567-72.
46.
Agrawal R., Marx A., Haller H.Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension . Hypertens2006;24:185-92.
47.
Poldermans D., Glazes R., Kargiannis S. et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther2007 ;29:279-89.
48.
Gennari C., Nami R., Pavese G., Gragnani S., Bianchini C., Buracchi P.Calcium-channel blockade (nitrendipine) in combination with ACE inhibition (captopril) in the treatment of mild to moderate hypertension. Cardiovasc Drug Ther1989;3(suppl 1):319-25.
49.
Messerli FHVasodilatory edema: a common side effect of antihypertensive therapy. Curr Cardiol Reports2002;4:479-82.
50.
Weir MR, Rosenberger C., Fink JCPilot study to evaluate a water displacement technique to compare effects of diuretics and ACE inhibitors to alleviate lower extremity edema due to dihydropyridine calcium antagonists. Am J Hypertens2001;14:963-8.
51.
Fogari R., Zoppi A., Derosa G. et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens2007;21:220-4.
52.
Waeber B., Burnier M., Brunner HRCompliance with antihypertensive therapy. Clin Exper Hypertens1999;21:973-85.
53.
Taylor AA, Shoheiber O.Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy. Congest Heart Fail2003;9:324-32.
54.
Lithell HOEffect of antihypertensive drugs on insulin, glucose, and lipid metabolism . Diabetes Care1991;14:203-09. 56. Burnier M. Angiotensin II type 1 receptor blockers. Circulation2001;103:904-12.
55.
Jandeleit-Dahm KA, Tikellis C., Reid CM, Johnston CI, Cooper MEWhy blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens2005;23:463-73.
56.
Elliott WJ, Meyer PMIncident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet2007;369: 201-07
57.
Bakris G., Molitch M., Hewkin A. et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care2006;29:2592-7.
58.
Bakris GL, Gaxiola E., Messerli FH et al. Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study. Hypertension2004;44:637-42.
59.
Mancia G., Messerli F., Bakris G., Zhou Q., Champion A., Pepine CJBlood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension2007;50:299-305.
60.
Cooper-Dehoff R., Cohen JD, Bakris GL et al. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). Am J Cardiol2006;98:890-4.
61.
Poulter NR, Wedel H., Dahlof B. et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet2005;366:907-13.
62.
O'Rourke M.Mechanical principles in arterial disease . Hypertension1995;26:2-9.
63.
Williams B. , Lacy PS, Thom SM et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation2006;113:1213-25.
64.
Jamerson KA , Bakris GL, Wun CC et al. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am J Hypertens2004;17:793-801.
65.
Jamerson K. , Bakris GL, Dahlof B. et al. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Pressure2007;16:80-6.
